+441518081136International Conference on Oncology & Cancer Therapy
March 18-19, 2019 | London, UK
Keynote
-
A prior activation of apoptosis pathways of tumor (AAAPT) technology: Biomarker for the risk stratification of cancer patients
J Med Oncl Ther
Raghu Pandurangi -
Cancer and peripheral deep vein thrombosis are both independent diseases: Causes, pathogenesis, conclusions
J Med Oncl Ther
Elena Drozdova -
Cancer metastasis from the primary site to the sentinel lymph nodes and beyond in relationship to the immune system
J Med Oncl Ther
Stanley P L Leong -
Change of the 2008/16 WHO into 2018 clinical, laboratory, molecular and pathobiological (WHO-CLMP) criteria for diagnosis of the meloproliferative neoplasms JAK2V617F trilinear polycythemia vera (PV), JAK2 exon 12 PV and JAK2V617F, CALR or MPL515 mutated thrombocythemias and secondary myelofibrosis
J Med Oncl Ther
Jan Jacques Michiels -
Disease modifying non-opioid analgesic for chemotherapy induced peripheral neuropathy (CIPN)
J Med Oncl Ther
Raghavan Rajagopalan -
Effects of far-infrared & terahertz Onnetsu therapy on various cancers, rheumatoid arthritis and other diseases
J Med Oncl Ther
Kazuko Tatsumura -
Finally we have positive data in the treatment of breast cancer using ICI
J Med Oncl Ther
Stefan Glueck -
Targeting RSK4 prevents both chemoresistance and metastasis in lung and bladder cancer: Potential of re-purposed floxacins as novel therapeutic agents
J Med Oncl Ther
Olivier E Pardo -
The mitotic kinase Aurora kinase A localises to mitochondria to control organelle dynamics and energy production: Implication for cancer cells overexpressing Aurora-A
J Med Oncl Ther
Claude Prigent -
The PVSG/WHO versus the clinical, laboratory, molecular and pathological (2018 CLMP) defined myeloproliferative neoplasms caused by JAK2V617F JAK2EXON12, CALR, MPL and TPO driver mutations are distinct blood & coagulation disorders: Prognostic and therapeutic implications towards 2020 and beyond
J Med Oncl Ther
Jan Jacques Michiels